Screener
Bioventus BVS Surgical Solutions — Total Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Net sales | $153,208 | $147,660 | $285,297 | $271,536 |
| Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively) | 47,542 | 45,570 | 88,862 | 86,390 |
| Gross profit | 105,666 | 102,090 | 196,435 | 185,146 |
| Selling, general and administrative expense | 82,740 | 79,110 | 161,065 | 152,612 |
| Research and development expense | 3,173 | 3,172 | 5,640 | 6,183 |
| Restructuring costs | (415) | — | 39 | — |
| Depreciation and amortization | 1,041 | 1,439 | 2,148 | 3,032 |
| Loss on disposals | — | 1 | — | 82 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's surgical solutions — total net sales?
- Bioventus (BVS) reported surgical solutions — total net sales of $50.35M in Q2 2026.
- How has Bioventus's surgical solutions — total net sales changed year-over-year?
- Bioventus's surgical solutions — total net sales decreased by 4.5% year-over-year, from $52.72M to $50.35M.
- What is the long-term trend for Bioventus's surgical solutions — total net sales?
- Over 4 years (2021 to 2025), Bioventus's surgical solutions — total net sales has grown at a 23.4% compound annual growth rate (CAGR), from $87.72M to $203.65M.
- What does surgical solutions — total net sales mean?
- This metric represents the total revenue generated from the sale of products and services within the surgical solutions business unit. It reflects the company's market performance and commercial success in providing specialized medical technologies for orthopedic and surgical procedures. Growth in this segment indicates successful adoption of the company's surgical portfolio by healthcare providers and surgeons.
Ask your AI about Bioventus's surgical solutions — total net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude